Q1 2025 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported a solid start to fiscal 2025 with total worldwide revenue of $67.5 million, representing a growth of just over 1% year-over-year.
- The med tech segment showed strong performance, growing approximately 9%, driven by products like Auryon and AlphaVac, which both grew over 20% in the quarter.
- Significant progress was made towards profitability, with an adjusted EBITDA loss of just $200,000, an improvement from the previous year.
- The company received CE mark approval for Auryon, opening access to the European PAD market, which is expected to contribute to revenue growth.
- AngioDynamics Inc (ANGO) is on track with its shift to outsourced manufacturing, expected to generate approximately $15 million in annualized savings by fiscal 2027.
- The med device segment experienced a revenue decline of approximately 4%, impacted by the timing of international orders and softness in microwave products.
- NanoKnife revenue declined by 6.9% due to a large European distributor's upfront inventory purchase in the prior year that did not recur.
- Gross margin decreased by 40 basis points year-over-year, affected by increased hardware depreciation and inflationary pressures.
- The company reported an adjusted net loss of $4.4 million for the first quarter of FY 2025, although this was an improvement from the previous year.
- Cash and cash equivalents decreased significantly from $76.1 million at the end of May 2024 to $55 million at the end of August 2024, with a high cash utilization in the first quarter.
Good morning, and welcome to the AngioDynamics fiscal year 2025 first quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded.
The news release detailing AngioDynamics' fiscal 2025 first quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the Investors section of the company's website at www.angiodynamics.com, and a webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events including statements about expected revenue, adjusted earnings, and gross margins for fiscal year 2025 as well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC including, without
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
